Herbs (Global Traditional) · Amazonian
Matico (Piper aduncum) (Piper aduncum)
Moderate Evidencebotanical1 PubMed Study
Hermetica Superfood Encyclopedia
Matico (Piper aduncum) is an Amazonian herb containing essential oils like nerolidol and beta-caryophyllene that demonstrate antimicrobial and anti-inflammatory properties. The beta-caryophyllene component modulates the endocannabinoid system through CB2 receptor activation.
Matico (Piper aduncum) is an evergreen shrub native to the Amazonian region, growing abundantly in tropical zones from Mexico to Argentina, the Caribbean, and parts of South Asia. The leaves are harvested and typically prepared as infusions, powders, poultices, capsules, or essential oils through drying, crushing, or steam distillation processes.
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on Matico according to available research. Evidence is limited to traditional use reports, in vitro investigations, and animal studies examining antimicrobial and anti-inflammatory effects.
No clinically studied dosage ranges are available due to lack of human trials. Traditional forms include hot infusions of dried leaves, powders, capsules in unspecified "standardized doses," poultices for topical use, and diluted essential oil preparations. Consult a healthcare provider before starting any new supplement.
Matico (Piper aduncum) is a medicinal herb primarily valued for its bioactive phytochemicals rather than macronutrient content. As a leaf-based botanical, dried leaf material contains estimated crude fiber (15–25% dry weight), modest protein (8–12% dry weight), and minimal fat (2–5% dry weight) typical of Piperaceae family foliage, though precise macronutrient data for this specific species is limited in peer-reviewed literature. Key bioactive compounds are well-characterized: Essential oil fraction (0.5–3.5% yield from fresh leaves) is dominated by dillapiole (reported at 40–80% of essential oil composition in Amazonian chemotypes), with secondary constituents including nerolidol (up to 15%), beta-caryophyllene (3–10%), and apiole (<5%). Flavonoids present include quercetin and kaempferol glycosides, consistent with other Piper species, at estimated concentrations of 0.1–0.5% dry weight. Phenylpropanoids, particularly chromenes and chalcones, have been isolated from leaf extracts. Tannins are present at approximately 2–6% dry weight, contributing to the plant's astringent properties. Mineral content is not specifically documented for P. aduncum, but Piper genus leaves generally contain potassium, calcium, and magnesium at trace-to-moderate levels. Bioavailability note: Essential oil compounds like dillapiole and beta-caryophyllene are lipophilic and exhibit enhanced absorption with fatty food matrices; aqueous traditional infusions capture primarily water-soluble flavonoids and tannins but have limited extraction of terpenoid-rich essential oil fractions.
Matico's beta-caryophyllene acts as a selective CB2 cannabinoid receptor agonist, reducing inflammatory cytokine production and modulating immune responses. The essential oil compound nerolidol disrupts bacterial cell membrane integrity and inhibits biofilm formation. Traditional diuretic effects may occur through increased renal sodium excretion, though the exact mechanism remains unclear.
Current evidence for matico is limited to in vitro antimicrobial studies and animal inflammation models, with no human clinical trials published. Laboratory studies show essential oil concentrations of 0.1-1.0% inhibiting various bacterial strains including Staphylococcus aureus. Animal studies using 100-300mg/kg doses demonstrated reduced inflammatory markers, but human safety and efficacy remain unestablished. Traditional use evidence exists for urinary tract applications, but lacks controlled study validation.
Safety data for matico supplementation is extremely limited due to lack of human studies. Potential interactions may occur with anticoagulant medications due to beta-caryophyllene's effects on platelet aggregation. Pregnancy and breastfeeding safety is unknown, so use should be avoided during these periods. Individuals with CB2 receptor-affecting medications should consult healthcare providers before use.
